Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Evidence suggests that anti-inflammatory medication may be effective in the treatment of depressive symptoms. In this study, we aimed to investigate whether minocycline added to treatment as usual (TAU) for 3 months in patients with treatment-resistant depression will lead to an improvement in depressive symptoms. Methods: Multi-site, 12-week, double-blind, placebo-controlled, pilot trial of minocycline added to TAU for patients suffering from DSM-5 major depressive disorder, whose current episode has failed to respond to at least two antidepressants. The primary outcome measure was mean change in Hamilton Depression Rating Scale (HAMD-17) scores from baseline to week 12. Secondary measures were the Clinical Global Impression scale (CGI), Patient Health Questionnaire-9 (PHQ-9), the Generalised Anxiety Disorder scale (GAD-7) and EuroQoL (EQ-5D) quality-of-life questionnaire. Side-effect checklists were also used. Minocycline was started at 100 mg once daily (OD) and increased to 200 mg after 2 weeks. Results: A total of 41 participants were randomised, with 21 in the minocycline group and 20 in the placebo group. A large decrease in HAMD scores was observed in the minocycline group compared to the placebo group (standardised effect size (ES) –1.21, p < 0.001). CGI scores in the minocycline group also showed a large improvement compared with placebo (odds ratio (OR): 17.6, p < 0.001). PHQ-9, GAD-7 and EQ-5D total showed more moderate improvements (ES ~ 0.4–0.5). Conclusion: The findings indicate that adjunctive minocycline leads to improvement in symptoms of treatment-resistant depression. However, our findings require replication in a larger sample. Trial Registration: ClinicalTrials.gov identifier: NCT02263872, registered October 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815 · cited 1×
“…and Targum, 2007); the Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001) a self-rated depression severity measure; the GAD-7 (Spitzer et al., 2006), a measure of generalised anxiety disorder, and the EuroQoL (EQ-5D) scale, a measure of health-related quality of life (Brooks, 1996).”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 5×
“Minocycline is an inhibitor of microglial activation (Soczynska et al., 2012) and has been shown to decrease depressive and anxiety symptoms in mice whist reducing pro-inflammatory cytokines (i.e. tumour necrosis factor (TNF) and interleukin (IL)-1B) and glucocorticoids (Majidi et al., 2016).”
ResultInfluentialO'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278 · cited 3×
“Pro-inflammatory cytokines can activate the enzyme indoleamine 2,3-dioxygenase (IDO).”
BackgroundKhandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846 · cited 1×
“Longitudinal studies have demonstrated that high plasma pro-inflammatory protein levels precede, and thus potentially cause depressive symptoms (Gimeno et al., 2009; Khandaker et al., 2014).”
BackgroundMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Cited by
McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Metadata
- Authors
- Husain, M. I., Chaudhry, I. B., Husain, N., Khoso, A. B., Rahman, R. R., Hamirani, M. M., Hodsoll, J., Qurashi, I., Deakin, J. F., & Young, A. H.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-08-31
- Volume
- 31
- Issue
- 9
- Pages
- 1166-1175
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2753594835
- Cited by
- 144
- References
- 17
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1177/0269881117724352
- The paper
- Husain, M. I., Chaudhry, I. B., Husain, N., Khoso, A. B., Rahman, R. R., Hamirani, M. M., Hodsoll, J., Qurashi, I., Deakin, J. F., & Young, A. H. (2017). Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117724352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.